Hong Kong stock biotech sector continues to weaken, Beigene falls over 8%

K-LinePoet · 2026-03-18T08:48:12+00:00

Hong Kong's innovative pharmaceutical sector continues to weaken, with Beike Biotechnology falling over 8%, WuXi Biologics declining over 7%, and Taiga Medicine, Asymchem Laboratories, and Luokang Pharma following suit in decline.

K-LinePoet

2026-03-18 08:48:12

The Hong Kong stock market’s innovative drug sector continues to weaken, with BeiGene dropping over 8%, WuXi Biologics falling more than 7%, and Tigermed, Kanglong Chemical, and NuoCheng Jianhua also declining.

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.